Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2025 10:00 ET | Source: NanoNewron

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program

NanoNewron awarded a $2.5 million NIH grant to develop TNF-α inhibitors engineered to cross the Blood-Brain Barrier to treat Alzheimer’s disease
August 06, 2025 11:29 ET | Source: Spherix Global Insights

Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors...
July 24, 2025 06:16 ET | Source: Research and Markets

Behcet's Disease Market Research Report 2025-2035 | Key Trends, Regulatory Framework, Epidemiology, Clinical Trial Analysis, Market Dynamics

Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Behcet's Disease Market - A Global and Regional Analysis: Focus on Distribution Channel, Route of Administration, Type, Country, and Region - Analysis...
May 15, 2025 09:54 ET | Source: Research and Markets

Enbrel (Etanercept) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F

Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Enbrel (Etanercept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...
April 30, 2025 06:42 ET | Source: Research and Markets

Inflammatory Bowel Disease (IBD) Treatment Market 2025-2035: Biologics and Novel Drug Classes Propel IBD Treatment Market Forward

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market - A Global and Regional Analysis: Focus on Route of Administration, Drug Class, Distribution Channel,...
March 04, 2025 15:13 ET | Source: NanoNewron

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound

Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier
January 16, 2025 04:02 ET | Source: Research and Markets

Systemic Lupus Erythematosus (SLE) Market Forecast at $6.19 Billion by 2034: In-Depth Analysis by Drug Class, Route of Administration, Distribution Channel and Region

Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "Systemic Lupus Erythematosus Market by Drug Class, Route of Administration, Distribution Channel, and Region" report has been added to ...
June 25, 2024 10:57 ET | Source: Research and Markets

U.S. Inflammatory Bowel Disease Treatment Market Trends Analysis Report 2024-2030 Featuring Biogen, Novartis, Eli Lilly & Co, UCB, Celltrion, Merck & Co, and Johnson & Johnson

Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class, Route Of Administration, Distribution...
January 23, 2024 11:48 ET | Source: Research and Markets

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Outlook 2024-2028: Product Innovations and Strategic Partnerships Catalyzing Industry Growth

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The tumor necrosis...
January 22, 2024 10:47 ET | Source: Spherix Global Insights

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld their...